Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VioQuest Pharmaceuticals and the US National Cancer Institute or NCI have entered into a clinical trial agreement for the company's product candidate VQD-002 or triciribine phosphate monohydrate.
Subscribe to our email newsletter
The agreement provides for the NCI to sponsor a clinical trial of VQD-002 in combination with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor. Recent reports have shown that the sensitivity of multiple types of solid tumors to EGFR inhibitors is dependent on inhibition of the PI3K pathway, suggesting that VQD-002 might be clinically useful to enhance response to erlotinib.
Michael Becker, president and CEO of VioQuest, said: “Through this agreement, we expand the clinical development opportunities for VQD-002 and gain access to the NCI’s broad network of scientists conducting NCI-sponsored clinical trials.”